Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-04-28
2000-09-05
Fonda, Kathleen K.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 31335
Patent
active
061143766
ABSTRACT:
This invention describes methods for increasing the toxicity of a cytostatic hydrophobic chemotherapeutic agent against resistant tumor cells in mammals which comprise administering a multidrug resistant reversing agent to the mammal in connection with the administration of the cytostatic hydrophobic chemotherapeutic agent in an amount effective to increase the toxicity of the chemotherapeutic agent, wherein the multidrug resistant reversing agent is a macrocyclic lactone compound. Examples of the macrocyclic lactone compounds useful in the present invention include, but are not limited to, the LL-F28249.alpha.-.lambda. series of compounds, the 23-oxo or 23-imino derivative thereof, the avermectins, the 22,23-dihydro derivatives thereof and the milbemycins. Compositions comprising the macrocyclic lactone compounds and the chemotherapeutic agents are also described herein.
REFERENCES:
patent: 3950360 (1976-04-01), Aoki et al.
patent: 4199569 (1980-04-01), Chabala et al.
patent: 4310519 (1982-01-01), Albers-Schonberg et al.
patent: 4916154 (1990-04-01), Asato et al.
patent: 5106994 (1992-04-01), Carter et al.
patent: 5169956 (1992-12-01), Carter et al.
patent: 5578637 (1996-11-01), Lai et al.
Pouliot et al., Reversal of P-Glycoprotein-Associated Multidrug Resistance by Ivermectin, Biochem. Pharm. 53(1):17-25 (Jan. 10, 1997).
Greenwald et al., Mechanistic Studies of Passive and Active Transport Processes in MDCK Cells: Transport of Selected Anthelmintics, oral presentation at 41st Annual Meeting, Jul. 20-23, 1996 (KY) AAVP Proceedings abstr. 12.
Didier et al., The abamectin derivative ivermectin is a potent P-glycoprotein inhibitor, Anti-Cancer Drugs 7:745-751 (1996).
Didier et al., Decreased uptake of cyclosporin A by P-glycoprotein (Pgp) expressing CEM leukemic cells & restoration of normal retention by Pgp blockers, Anti-Cancer Drugs 6:669-680 (1995).
Didier et al., Decreased biotolerability for ivermectin & cyclosporin A in mice exposed to potent P-glycoprotein inhibitors, Int. J. Cancer 63:263-267 (1995).
Schinkel et al., Disruption of the Mouse mdr1a P-Glycoprotein Gene Leads to a Deficiency in the Blood-Brain Barrier and to Increased Sensitivity to Drugs, Cell 77:491-502 (May 20, 1994).
Georges Elias
Pouliot Jean-Fran.cedilla.ois
Prichard Roger K.
Fonda Kathleen K.
McGill University
Rosenblum Anne M.
LandOfFree
Methods for using macrocyclic lactone compounds as multidrug res does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for using macrocyclic lactone compounds as multidrug res, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for using macrocyclic lactone compounds as multidrug res will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2212585